TMCnet News
AXIM® Biotech Receives Medical Ethical Committee Approval to Begin IBS Trial for Canchew Plus® CBDGumNEW YORK, Dec. 06, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it received approval from the Medical Ethical Committee (METC) of Wageningen University, The Netherlands, to begin a study on patients suffering from irritable bowel syndrome (IBS) with the Company’s CanChew Plus® CBD-containing chewing gum. “Combined with previously announced PK studies, the METC approval marks another key step toward clinical trials for a cannabis-based treatment for the most common functional gastrointestinal disorder in the world,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “The global treatment market for irritable bowel syndrome is estimated to grow in value to $1.5 billion by 2023. We believe that our CanChew Plus® and other cannabis-based products provide viable solutions for suffering patients.” “Further, our goal is to help people suffering from various gastrointestinal disorders with no effective remedies such as IBD and Crohn’s disease. With positive outcome from the IBS studies, we would immediately enter trials for inflammatory bowel disease (IBD) and Crohn’s disease.” METC at Wageningen University is an institutional approval board that is compliant with the Ethical Principles for Medical Research adopted at the 18th World Medical Association (WMA) General Assembly in Helsinki, Finland, in June 1964. Wageningen University is a world-class education and research institute in the field of life sciences, agricultural andenvironmental science, and the only university in The Netherlands to focus on the theme of “healthy food and living environment.” According to the Times Higher Education World University Rankings, Wageningen is the best university in The Netherlands and No. 1 worldwide in agriculture and forestry for 2016 on the QS World University Rankings. About AXIM® About CanChew® and CanChew Plus® CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:
CanChew Plus® is a vastly improved delivery system than the alpha version of CanChew® Gum. It is produced by a leading European functional gum manufacturer. Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLivinG Foundation and honored with its Triple Leaf Award. Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 [email protected] www.cmwmedia.com Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227 |